Related Experiment Video
Updated: Jun 11, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Portacaths are safe for long-term regular blood transfusion in children with sickle cell anaemia
Jack L Bartram1, Sandra O'Driscoll, Austin G Kulasekararaj
1Department of Paediatric Haematology, King's College London School of Medicine, King's College Hospital, Denmark Hill, London SE5 9RS, UK. jacklbartram@hotmail.com
Insights
Totally implantable venous access devices, Portacaths (PAC), offer a safe and reliable solution for children with sickle cell anaemia (SCA) needing frequent blood transfusions. This study found low complication rates, making PACs a viable option when peripheral venous access is challenging.
Area of Science:
- Pediatric Hematology
- Vascular Access Devices
- Sickle Cell Disease Management
Background:
- Peripheral venous access is challenging in children with sickle cell anaemia (SCA) requiring frequent blood transfusions.
- Previous use of Portacaths (PAC) in this population was associated with high complication rates.
Purpose of the Study:
- To evaluate the safety and efficacy of totally implantable venous access devices (Portacaths) in children with SCA.
- To assess complication rates, including infection and thrombosis, associated with PAC use in this specific patient group.
Main Methods:
- A retrospective review of seven children with SCA who received PAC insertion over a 9-year period.
- Data collected included PAC days, age at insertion, duration of device use, and complication events (infection, thrombosis).
Main Results:
- Seven PAC devices were used for a total of 9754 PAC days.
- The median age at insertion was 6.3 years.
- The PAC-associated infection rate was low at 0.2 per 1000 PAC days, with no episodes of thrombosis.
Conclusions:
- Totally implantable venous access devices (Portacaths) can be used safely and reliably in children with SCA.
- PACs provide a crucial solution for managing difficult venous access in pediatric patients undergoing regular blood transfusions for sickle cell anaemia.
Abstract:
Peripheral venous access in children with sickle cell anaemia (SCA) requiring regular blood transfusions can become difficult over time. Previous reports have suggested the use of totally implantable venous access devices, Portacaths (PAC) in this patient group are associated with unacceptable high rates of complications. We present our experience in seven children with SCA over a 9-year period. Seven devices were placed for a total of 9754 PAC days during the study period. The median age at insertion was 6.3 years (range 3-15 years). The rate of PAC associated infection was 0.2 per 1000 PAC days. There were no episodes of thrombosis. The median length of time in situ during the study period was 3.7 years (range 1.3-7.5 years). Our experience highlights the safe and reliable use of PAC in children with SCA requiring regular blood transfusions when venous access has become a major problem.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Continuous Renal Replacement Therapy
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
